Establishing Frameworks for Precision Medicine in NTRK Fusion-Positive Advanced Solid Tumors
| Overview / Abstract: |
Despite significant advancements over the past decade, significant unmet needs persist for patients with NTRK-positive locally advanced or metastatic solid tumors. In addition, there is ongoing debate about the importance of testing for genomic alterations in rare cancers, or those that rarely occur in common cancers. However, evolving molecular testing procedures and emerging therapeutic options targeting NTRK fusions offer new pathways for the detection and treatment of these cancers. To help clinicians enhance their diagnostic-therapeutic paradigms for rare genomic alterations, this interactive practice guide interweaves education and practical guidance for easy integration of the latest testing and treatment strategies within daily clinical processes and workflows. |
|
Expiration |
Aug 15, 2025 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1 |
|
Accreditation |
AACME, MIPS QPP |
|
Presenters / Authors / Faculty |
Alexander Drilon, MD Jeremy Segal, MD, PhD |
|
Sponsors / Supporters / Grant Providers |
Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Bristol Myers Squibb. |
|
Keywords / Search Terms |
ACHL CME, CE, MD Anderson, BMS, Drilon, Segal, NTRK, TRK inhibitors, fusion-positive, NTRK-positive, genomic, gene fusions, secretory breast carcinoma, mammary analogue secretory carcinoma, infantile fibrosarcoma, tropomyosin receptor kinase Free CE CME |
|